- Home
- TMC vs VRDN Comparison
TMC vs VRDN Comparison
Compare TMC & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMC | VRDN |
|---|---|---|
| Founded | 2011 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TMC | VRDN |
|---|---|---|
| Price | $4.48 | $22.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 14 |
| Target Price | $8.85 | ★ $35.46 |
| AVG Volume (30 Days) | ★ 4.1M | 1.9M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 232.00 | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | ★ $5,706,000.00 |
| Revenue This Year | N/A | $13.73 |
| Revenue Next Year | N/A | $279.00 |
| P/E Ratio | $91.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.40 | $13.18 |
| 52 Week High | $11.35 | $34.29 |
Technical Indicators
Market Signals| Indicator | TMC | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 58.36 | 72.58 |
| Support Level | $4.24 | $22.14 |
| Resistance Level | $4.89 | $34.18 |
| Average True Range (ATR) | 0.24 | 0.96 |
| MACD | 0.14 | 0.31 |
| Stochastic Oscillator | 80.52 | 83.79 |
Price Performance
Historical ComparisonAbout TMC TMC the metals company Inc.
TMC The Metals Co Inc is a deep seabed minerals developer focused on the collection, processing and refining of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone (CCZ), approximately 1,500 miles (or 2,400 kilometers) south-west of San Diego, California. The company operates as a single operating and reportable segment, namely exploration of seafloor polymetallic nodules, which includes the development of a metallurgical process to treat such seafloor polymetallic nodules.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.